Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). - Wikidata - wikimedia - TriplyDB

Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6).

Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6).

http://www.wikidata.org/entity/Q37200840

about

15-lipoxygenase metabolites of docosahexaenoic acid inhibit prostate cancer cell proliferation and survival A review of the biologic and pharmacologic role of docosapentaenoic acid n-3 Specialized pro-resolving lipid mediators in the inflammatory response: An update Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation.Omega-6 docosapentaenoic acid-derived resolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis.Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states.Resolvins and protectins in inflammation resolution.Regulation of rat brain polyunsaturated fatty acid (PUFA) metabolism during graded dietary n-3 PUFA deprivation.(n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?Fifteen weeks of dietary n-3 polyunsaturated fatty acid deprivation increase turnover of n-6 docosapentaenoic acid in rat-brain phospholipids.Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling.Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation.Increased ω6-Containing Phospholipids and Primary ω6 Oxidation Products in the Brain Tissue of Rats on an ω3-Deficient Diet Lipidomics of essential fatty acids and oxygenated metabolites.LC/ESR/MS study of pH-dependent radical generation from 15-LOX-catalyzed DPA peroxidation.Controlled formation of mono- and dihydroxy-resolvins from EPA and DHA using soybean 15-lipoxygenase Dietary PUFAs attenuate NLRP3 inflammasome activation via enhancing macrophage autophagy.Orally administered [¹⁴C]DPA and [¹⁴C]DHA are metabolised differently to [¹⁴C]EPA in rats.ALOX15 oxidises DPAn-6 to 17(S)-HDPAn-6 and 10(S);17(S)-diHDPAn-6 ALOX12:Fe2+ oxidises DPAn-6 to 14(S)-HDPAn-6

P2860

Q21134042-FE04A7E9-C756-4871-9C8A-CC5466A40BF1 Q28248251-59AA0146-85F0-48CB-84BA-94C2CF00A214 Q33657562-DE8D2E3E-27A8-4369-BC51-053BB88A2C8D Q33683210-2E05BDA5-BE9C-402E-B693-86E4CDAB8E22 Q33784486-504E039D-0A23-4C80-BB38-9CA49A969118 Q34276710-38B226B1-12BA-484C-98F3-5DB4F00E0A45 Q35030324-A665AE9E-3A6E-4E9C-A805-7FC548439722 Q35332873-C5635163-108D-46F4-B63C-4C39D56DBDD5 Q35529104-ACFE721E-0CC5-475A-A12E-1A1B80C46659 Q35753222-735F4F09-4B81-4D6D-AC2B-37C4639A95EC Q35946492-9FF24913-18D6-4082-A229-7670EABDC6C7 Q36001468-A4CF067B-CCEF-42A6-B71B-98B075B3B372 Q36012382-85ECC7C1-F70C-40BA-B987-A5C07CE92607 Q36176078-C1A09D10-81DA-46FE-8877-F00F03A08AB7 Q38118674-B66930EC-686B-4577-AD49-08E1E2566A25 Q38270838-F72943E9-A334-4E89-BEA7-F4B27ABB23A8 Q39741987-6D3C6974-4F98-4E7F-8E8B-AB61447D5A58 Q42771466-9AC26709-0E9D-4B52-9350-B3AE076949FB Q48518422-D5FADA22-7E9B-4ACB-874B-861B23D3A3A9 Q55216546-73819543-4D67-49F0-95A9-137B4EAAF4B0 Q55216547-636253F0-48FE-4834-ABFE-D5F1ED3CDDD5

P2860

Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6).

http://www.wikidata.org/entity/Q37200840

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biogenic synthesis, purificati ...... ocosapentaenoic acid (DPAn-6).

@en

Biogenic synthesis, purificati ...... ocosapentaenoic acid (DPAn-6).

@nl

type

label

Biogenic synthesis, purificati ...... ocosapentaenoic acid (DPAn-6).

@en

Biogenic synthesis, purificati ...... ocosapentaenoic acid (DPAn-6).

@nl

prefLabel

Biogenic synthesis, purificati ...... ocosapentaenoic acid (DPAn-6).

@en

Biogenic synthesis, purificati ...... ocosapentaenoic acid (DPAn-6).

@nl

P1433

Q37200840-6A1EFA4A-2284-4ACA-B804-6934046E997D

P1476

Q37200840-AC291B20-4D07-4D95-9A39-AC5B39199711

P2093

Q37200840-15FF10F6-6B9B-47CA-9583-D7CB323E11DE

Q37200840-19ED8C7E-F74F-4325-AB85-C0C646FF0DEA

Q37200840-388F9815-6627-42C8-BC0D-C323AD77CB2C

Q37200840-3E36C627-7192-469D-8567-E8E24879B8DF

Q37200840-4B38EAC8-F218-4FCC-AFFF-855631B1ABC1

Q37200840-8858FD91-AF95-4F62-B2AB-24C4553E0B9F

Q37200840-F98BD8E0-14F9-486E-B3DA-E71D9DD464FA

P2860

Q37200840-015E95EF-A255-4A18-ACAE-FF123338F749

Q37200840-05DFA134-A623-4801-B0DA-AC2FEDDCBADB

Q37200840-0B5756E7-F1E6-493C-AF06-3FAD9EE23C45

Q37200840-0EC0D7D3-DE79-4FD5-AF55-DBA416A7C84D

Q37200840-167EB77E-9480-4365-922E-C7B5808EE151

Q37200840-1E063F7B-FAAF-4967-98B1-9B289536BCB5

Q37200840-20282AAF-2924-46D1-9E04-45D593C4626E

Q37200840-27306846-A35A-41CE-A083-3CF9238FDD5D

Q37200840-287F1710-913E-44C9-BC14-ED1E56C98319

Q37200840-39516763-F635-47E2-9D09-F9941D82BFF0

P304

Q37200840-5540219C-B05D-484B-AD25-1A14606E3F6D

P31

Q37200840-6B8ACCD6-6889-4F54-842B-4812DDD7885E

P356

Q37200840-071912BE-C6EF-4473-8021-54F77FCAD55A

P407

Q37200840-12BD1201-EA25-4198-9301-30C0E46456C2

P433

Q37200840-D6C54C63-28B6-4067-99AC-A89437B616EF

P478

Q37200840-0BE066A2-6BED-462A-A5E5-69509193C164

P577

Q37200840-45071260-4AF6-440B-8355-A65315551B99

P698

Q37200840-9B89DB52-EC78-4A9B-A8DE-31586C08530E

P921

Q37200840-12F40099-ED77-4358-979F-9035D3BAAD50

Q37200840-3BC76317-E85B-46D9-B37E-96BBC0A3D811

Q37200840-5C99D909-0B11-45E7-862F-ED47819F1A82

Q37200840-73322C95-6F14-4370-B673-7C26C4FFBF88

Q37200840-82789ED3-2A09-4927-8685-E9F1B71BBD44

Q37200840-8D3B954A-947F-470F-8CED-0CCC57C57720

Q37200840-A12CACD2-A5D0-4180-9E31-2C8E7E292FBC

Q37200840-DE8D4067-3A63-4B29-84C1-180F7EE28798

Q37200840-FD0FCAF6-C465-42D6-A812-A0EE811A6E58

Q37200840-FD5E59B4-049A-4F97-8C57-FC6AED7D614F

P932

Q37200840-A098208D-D5D2-4C85-B168-F671E26B246A

P356

P1433

Journal of Biological Chemistry

P1476

Biogenic synthesis, purificati ...... ocosapentaenoic acid (DPAn-6).

@en

P2093

Bindi Dangi

http://www.w3.org/2001/XMLSchema#string

Julie M Nauroth

http://www.w3.org/2001/XMLSchema#string

Krishna Raman

http://www.w3.org/2001/XMLSchema#string

Linda M Arterburn

http://www.w3.org/2001/XMLSchema#string

Mah Teymourlouei

http://www.w3.org/2001/XMLSchema#string

Marcus Obeng

http://www.w3.org/2001/XMLSchema#string

Micah Needham

http://www.w3.org/2001/XMLSchema#string

P2860

Amaranth oil application for coronary heart disease and hypertension

Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress

Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis

Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution

Lipoxins and aspirin-triggered lipoxins in airway responses

Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression

Novel chemical mediators in the resolution of inflammation: resolvins and protectins

Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation

P304

14744-14759

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M809014200

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19324874

http://www.w3.org/2001/XMLSchema#string

P921

(4Z,7Z,11Z,13Z,15E,17S,19Z)-10,17-bis(hydroperoxy)docosahexaenoate

(7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosapentaenoate

(7Z,11Z,13Z,15E,19Z)-10,17-bis(hydroperoxy)docosapentaenoate

(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosahexaenoate

(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosapentaenoate

(4Z,7Z,10Z,13Z,15E,17S)-17-hydroperoxydocosapentaenoate

(4Z,7Z,10Z,12E,16Z)-14-hydroperoxydocosapentaenoate

P932

2685656

http://www.w3.org/2001/XMLSchema#string